Carsgen announces the initiation of an investigator-initiated trial for an allogeneic cd19/cd20 car-t therapy

Shanghai , dec. 31, 2024 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (iit) in china for kj-c2219, an allogeneic car t-cell therapy, targeting cd19/cd20. the trial will evaluate kj-c2219 for the treatment of relapsed/refractory b-cell non-hodgkin lymphoma (r/r b-nhl).
CAR Ratings Summary
CAR Quant Ranking